Rare Disease/Gene Therapy

Focus Area Working Group

Strategic Mission & Objectives:: 

1. To create a community that advances our role as fully integrated strategic business partners to promote the growth of Medical Affairs Professionals within the Rare Disease/Gene Therapy sector worldwide.

2. To develop our Rare Disease/Gene Therapy community within MAPS to become the premier global destination of choice for Rare Disease/Gene Therapy MA professionals.

3. To catalyze our individual personal leadership development and professional career advancement.​

Activities: 

We will organize Rare Disease/Gene Therapy workshops for MAPS meetings in the North America, APAC (Asia Pacific – China/Japan), and EMEA (Europe, Middle-East, Asia) regions. We develop original content for webinars, podcasts, eLearning courses and white papers. In addition, the working group will periodically contribute cogent and timely content on the Rare Disease/Gene Therapy sector for the MAPS publication, Elevate magazine. Most importantly, we will provide a supportive resource for all Rare Disease/Gene Therapy Medical Affairs Professionals.​

Members

Ashish Dugar

Ashish Dugar

Senior Vice President, Global Head, Medical Affairs

Lead

Dyne Therapeutics

FAWG Overview

Rare Disease Updates

Adapting to the Virtual Conference Experience P2
, , , , , , , ,

Adapting to the Virtual Conference Experience P2

This MAPS podcast will explain how the in-person conference experience has changed and adapted to the virtual environment and discusses styles and formats that uniquely suit the online virtual conference experience
, , , , , , , , ,

The future is hybrid: why virtual events are here to stay

In this podcast sponsored by Impetus Digital, MAPS speaks about planning and delivering virtual and hybrid events with Impetus Digital Co-Founder and CEO, Natalie Yeadon.
Partnering for Today and Tomorrow - Episode 11 Clinical Operations
, , , , , , , ,

Partnering for Today and Tomorrow – Episode 11 Clinical Operations

This MAPS podcast discusses the functions and activities of key internal partners and Identifies potential areas for compliant collaboration by MSLs.
Isma Benattia, Vice President of Amgen Europe Medical Affairs, on the future of MSL - HCP interactions
, , , , , , , ,

Isma Benattia, Vice President of Amgen Europe Medical Affairs, on the future of MSL – HCP interactions

This Q&A describes Amgen Europe HCP preference survey results and wider changes in the way MSLs will work with their HCP peers as we emerge from the pandemic.
4 Habits to Optimize the Impact & the Value of Medical Affairs (MedEvoke PC Webinar)
, , , , ,

4 Habits to Optimize the Impact & the Value of Medical Affairs

The definition of a habit is a settled tendency or usual manner of behavior. This webinar seeks to evolve legacy expectations and drive forward habits for the individual medical affairs professional that will positively influence the overall community
Amgen Survey 2 Featured
, , , , , , , , , ,

A Year with COVID-19: Scientific Engagements Pulse Check

This paper describes survey results from Amgen JAPAC Medical Affairs examining the current state in early 2021 of medical engagement amongst healthcare professionals.
, , , , ,

Learnings from a practical experience of using NLP/ AI in Medical Affairs

Demonstrate the use of technology to automate part of the MLR Review and Approval process​ and learn how to provide details of a proof-of-concept to test AI-enabled technology in Medical Affairs.
Medical and AI Ethics
Adapting to the Virtual Conference Experience P1
, , , , , , , ,

Adapting to the Virtual Conference Experience P1

This MAPS podcast introduces listeners to social listening to gather insights and discusses implementation, value and technologies.

Lost your password? Please enter your username or email address. You will receive a link to create a new password via email.